CytomX jumps as investors react to fresh Varseta-M colorectal cancer update alongside FY2025 results

CytomX Therapeutics, Inc. (CTMX) is up 56.2% today. Here is some analysis on what might have caused this price movement.

Analysis: The surge appears tied to company-released updates that put the spotlight back on CytomX’s lead oncology asset, varsetatug masetecan (Varseta-M), alongside the company’s full-year 2025 financial results and corporate update. In early-stage biotech, a positive clinical-data headline can quickly re-rate expectations for partnering potential, trial expansion, and the probability of a registrational path.

Details:

The company issued a March 16, 2026 release discussing its 2025 financial results and providing a business update, which can reset investor expectations around cash runway, burn, and 2026 milestones.

A separate March 16, 2026 company announcement highlighted that Varseta-M (EpCAM PROBODY ADC) continues to show positive data supporting potential use in late-line colorectal cancer, which likely served as the primary sentiment driver.

Earlier company communications had framed a Phase 1 colorectal cancer expansion data update for Varseta-M as a key Q1 2026 catalyst, so the market may be treating this update as a meaningful de-risking event for the program’s next steps.

This could also be amplified by positioning/short-covering dynamics, given the stock’s history of large moves around clinical headlines (speculation).

Sources:

CytomX, GlobeNewswire, Nasdaq

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$CTMX Insider Trading Activity

$CTMX insiders have traded $CTMX stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.

Here’s a breakdown of recent trading of $CTMX stock by insiders over the last 6 months:

SEAN A. MCCARTHY (CEO) sold 101,793 shares for an estimated $461,906

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$CTMX Hedge Fund Activity

We have seen 73 institutional investors add shares of $CTMX stock to their portfolio, and 57 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

TANG CAPITAL MANAGEMENT LLC removed 11,065,662 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $47,139,720
FMR LLC added 9,291,909 shares (+60.4%) to their portfolio in Q4 2025, for an estimated $39,583,532
FRANKLIN RESOURCES INC removed 5,769,230 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $18,403,843
KYNAM CAPITAL MANAGEMENT, LP added 5,319,574 shares (+145.9%) to their portfolio in Q4 2025, for an estimated $22,661,385
ORBIMED ADVISORS LLC removed 4,935,850 shares (-58.3%) from their portfolio in Q4 2025, for an estimated $21,026,721
STATE STREET CORP added 4,495,949 shares (+697.1%) to their portfolio in Q4 2025, for an estimated $19,152,742
FAIRMOUNT FUNDS MANAGEMENT LLC removed 3,896,582 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $12,430,096

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$CTMX Analyst Ratings

Wall Street analysts have issued reports on $CTMX in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Barclays issued a "Overweight" rating on 01/20/2026
Guggenheim issued a "Buy" rating on 01/20/2026
Piper Sandler issued a "Overweight" rating on 01/20/2026
Cantor Fitzgerald issued a "Overweight" rating on 09/22/2025

To track analyst ratings and price targets for $CTMX, check out Quiver Quantitative's $CTMX forecast page.

$CTMX Price Targets

Multiple analysts have issued price targets for $CTMX recently. We have seen 5 analysts offer price targets for $CTMX in the last 6 months, with a median target of $10.0.

Here are some recent targets:

Michael Schmidt from Guggenheim set a target price of $10.0 on 03/09/2026
Etzer Darout from Barclays set a target price of $10.0 on 02/04/2026
Olivia Brayer from Cantor Fitzgerald set a target price of $10.0 on 02/04/2026
Joseph Catanzaro from Piper Sandler set a target price of $10.0 on 01/20/2026
Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $10.0 on 11/11/2025

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.